KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBT (2016 - 2025)

Pacira BioSciences has reported EBT over the past 16 years, most recently at $571000.0 for Q4 2025.

  • Quarterly results put EBT at $571000.0 for Q4 2025, down 97.76% from a year ago — trailing twelve months through Dec 2025 was $16.9 million (up 126.74% YoY), and the annual figure for FY2025 was $16.9 million, up 126.74%.
  • EBT for Q4 2025 was $571000.0 at Pacira BioSciences, down from $9.5 million in the prior quarter.
  • Over the last five years, EBT for PCRX hit a ceiling of $37.9 million in Q2 2023 and a floor of -$138.9 million in Q3 2024.
  • Median EBT over the past 5 years was $11.1 million (2021), compared with a mean of $4.3 million.
  • Biggest five-year swings in EBT: skyrocketed 702.37% in 2023 and later crashed 936.43% in 2024.
  • Pacira BioSciences' EBT stood at -$6.2 million in 2021, then crashed by 191.51% to -$18.1 million in 2022, then skyrocketed by 286.63% to $33.7 million in 2023, then fell by 24.3% to $25.5 million in 2024, then crashed by 97.76% to $571000.0 in 2025.
  • The last three reported values for EBT were $571000.0 (Q4 2025), $9.5 million (Q3 2025), and -$1.9 million (Q2 2025) per Business Quant data.